GlassScriptPhysician profile
Rachel M Decoster
NPI 1871902957
$5,529.99
in general payments reported to CMS, 2019-2025
28 companies · $1,037 in 2025
The $1,037 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $957 · 2022: $804 · 2023: $1,375 · 2024: $1,357 · 2025: $1,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,769.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,475.38 | 2021-2025 | |
| Pfizer INC. | $471.10 | 2023-2025 | |
| Glaxosmithkline, LLC. | $387.30 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $270.38 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $225.40 | 2023-2025 | Cardiomems, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $219.95 | 2022-2025 | |
| Lilly USA, LLC | $171.22 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceuticals, INC. | $166.34 | 2021 | |
| Insulet Corporation | $139.25 | 2023-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $127.13 | 2022-2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.58 | 2021-2024 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $118.20 | 2022-2023 | Seglentis, Livalo |
| Astrazeneca Pharmaceuticals LP | $113.99 | 2023-2025 | Airsupra, Fasenra, Farxiga |
| Axsome Therapeutics, INC. | $92.69 | 2023-2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $75.59 | 2023-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $75.00 | 2022-2024 | Myrbetriq, Veozah |
| Amgen INC. | $48.26 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.96 | 2024 | |
| Exact Sciences Corporation | $30.43 | 2023-2024 | Cologuard Collection Kit |
| Alnylam Pharmaceuticals INC. | $23.54 | 2025 | Givlaari |
| Boston Scientific Corporation | $23.29 | 2023 | Wavewriter Alpha Prime 16 |
| Bausch Health US, LLC | $19.22 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.73 | 2024 | Voquezna |
| Lundbeck LLC | $15.78 | 2023 | Rexulti |
| Evoke Pharma, INC. | $15.55 | 2023 | Gimoti |
| Takeda Pharmaceuticals U.S.A., INC. | $15.04 | 2023 | Aralast |
| Grifols USA, LLC | $13.66 | 2023 | Prolastin-C Liquid |
| Myovant Sciences INC. | $13.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Decoster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.